• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    AnnOncHo.pdf
    Size:
    129.6Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Ho, A. L.
    Bowles, D. W.
    Even, C.
    Hao, D.
    Kang, H.
    Metcalf, Robert
    Muzaffar, J.
    Oliva, M.
    Perez, C. A.
    Popovtzer, A.
    Rodriguez, C. P.
    Stemmer, S. M.
    Van Herpen, C. M.
    Winquist, E.
    Wirth, L. J.
    Worden, F. P.
    Xia, B.
    Gordon, G.
    Gordon, G. B.
    Ferrarotto, R.
    Show allShow less
    Affiliation
    Medicine, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, NY, USA
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background Notch signaling plays a key role in ACC tumorigenesis. Notchmut are found in ?20% of ACC tumors, which are aggressive with a poor prognosis (Ferrarotto 2016, Ho 2019). No therapies are approved for R/M ACC. AL101, an investigational ?-secretase inhibitor, blocks Notch signaling and inhibits tumors in ACC patient-derived xenograft models with Notchmut (AACR �19, Abstr 4885). AL101 has clinical activity at 4 mg once weekly (QW) with a disease control rate of 68% (15% partial response) and appears to be well tolerated (Ferrarotto ESMO �20, #919MO). Based on the safety and activity in the 4-mg cohort, a cohort of 42 additional subjects was added to evaluate treatment with 6 mg QW. Methods ACCURACY is an open-label, multicenter phase II study of AL101 (4 and 6 mg intravenous QW) in subjects with R/M ACC and known Notch1-4mut (ASCO �19, Abstr TPS6098). Subjects require evidence of disease progression within 6 months of entry or newly diagnosed metastatic disease and an ECOG performance status of 0-1. Primary end point was overall response rate (ORR) by RECIST v1.1 (or modified MD Anderson bone criteria), as assessed by investigators. Secondary end points were ORR by central review, duration of response, and safety. The study provides ?80% power to detect an increase of the ORR from 8% to 25% using a type I error of 5%. Results A total of 37 subjects were enrolled in the 6-mg QW cohort. Most common (?20%) treatment-related adverse events of all grades in the 6-mg cohort were diarrhea (73%; grade 3 (gr3) 11%), fatigue (49%; gr3 5%), nausea (41%; gr3 3%), hypophosphatemia (27%; gr3 0%), vomiting (27%; gr3 0%), decreased appetite (22%; gr3 3%), and rash (22%; gr3 0%). Conclusions AL101 6 mg QW appears to be well tolerated in Notchmut R/M ACC. Efficacy and pharmacokinetic data will be presented. Accrual and follow-up to the 6-mg cohort is ongoing.
    Citation
    Ho AL, Bowles DW, Even C, Hao D, Kang H, Metcalf R, et al. 904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S803�4.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624715
    DOI
    10.1016/j.annonc.2021.08.1314
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.08.1314
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.08.1314
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.